Bioextrax reported an eventful Q4 2025, with EBIT of MSEK -5.0, slightly higher than expected. Cash at year-end amounted to MSEK 3.9, with MSEK 12.5 from the rights issue recorded as a recievable. The company is awaiting an agreement with Chematur regarding a PHBV facility in Asia, and has initiated a project with Lantmännen to trial protein from feathers in animal feed. Panel testing at the candy company has not yet started.
Read the full report here.